期刊文献+

慢性丙型肝炎病毒感染患者血清IL-35表达水平及其意义

IL-35 expression levers in serum and its significance in patients with chronic hepatitis C virus infection
下载PDF
导出
摘要 目的:通过检测慢性丙型肝炎病毒(HCV)感染者血清中白细胞介素-35(IL-35)的表达水平,探讨IL-35在HCV持续感染致病机制中的作用。方法:用酶联免疫吸附试验(ELISA)法检测263例慢性丙型肝炎患者和117例健康体检者的血清IL-35水平,并对不同临床诊断的HCV患者间的IL-35水平进行比较分析,同时分析IL-35与ALT、AST、TBIL、ALB和HCVRNA的相关性。结果:HCV感染者血清IL-35水平明显增高,高于健康对照者,其中HCV相关的肝癌IL-35水平最高3926.1(297.2-4129.1)pg/ml,明显高于肝硬化2497.1(117.2-3491.3)pg/ml和慢性肝炎组1987.6(89.69-2987.3)pg/ml。结论:HCV感染者血清中IL-35水平明显升高,提示IL-35在HCV持续感染的免疫致病机制中起着一定作用,为临床诊断和治疗HCV感染提供了一种思路。 Objective:Through the detection of chronic hepatitis C virus(HCV)infection interleukin in serum vitamin-35(IL-35)expression levels of IL-35 inpersistent HCV infection,to explore the pathogenesis mechanism.Methods:With the method of enzyme linked immunosorbent assay(ELISA)method was used to detect the serum IL-35 level in 263 patients with chronic hepatitis C patients and 117 healthy,and the different clinical diagnosed HCV patients and the level of IL-35 were compared and analyzed,and the analysis of the IL-35 and the ALT,AST,TBIL,the correlation between ALB and HCVRNA.Results :The serum IL-35 levels of HCV infection increased significantly,higher than that of healthy controls group,where HCV related hepatocellular carcinoma IL-35 highest level in 3926.1(297.2-4129.1)pg/ml was significantly higher than that in liver cirrhosis,2497.1(117.2-3491.3)pg/ml and chronic hepatitis B group was 1987.6(89.69-2987.3)pg/ml.Conclusion:The level of serum IL-35 is significantly increased in conclusion HCV infection,suggesting that IL-35 plays a role in the immune pathogenesis of HCV persistent infection,and provides a new idea for clinical diagnosis and treatment of the treatment of HCV infection.
出处 《陕西医学杂志》 CAS 2015年第3期289-291,共3页 Shaanxi Medical Journal
关键词 丙型肝炎病毒 白细胞介素-35/分析 病毒感染/病理生理学 Hepacivirus Interleukin-35 / analysis Virus infections / physiopathology
  • 相关文献

参考文献8

  • 1Chinese Society of Hepatology and Chinese Society of In- fectious Diseases and Parasitology of Chinese Medical As- sociation. The guideline for prevention andtreatment of hepatitis C[J]. Chin J Hepatol, 2004, 12: 194-198.
  • 2Yang XO, Nurieva R, Marfinez CJ, etal. Molecular an- tagonism and plasticity of regulatory and inflammatory T cell programs[J]. Immunology,2008, (29) : 44-56.
  • 3Collison LW, Workman CJ, Kuo TT, et al. The inhibi- tory cytokine IL-35 contributes to regulatory T-cell func- tion[J]. Nature, 2007, 450.-566-569.
  • 4Caridade M, Graca L, Ribeiro RM. Mechanisms under- lying CD4+ treg immune regulation in the adult: From experiments to models[J]. Front Immunol, 2013, 18 (4) : 378.
  • 5Yeh H, Moore DJ, Markmann JF,etal. Mechanisms of regulatory T cell counter-regulation by innate immunity [J]. Transplant Rev, 2013,27(2) :61-4.
  • 6Niedbala W, Wei X, Cai B, et al. IL-35 is a novel cyto- kine with therapeutic effects thritis through the expansion against collagen-induced ar of egulation T cells and sup pression of Th17 cells[J]. European J Immunol, 2007, 37 (11) : 3021-3029.
  • 7Thiolat A, Denys A, Petit M, et al. Interleukin-35 gene therapy exacerbates experimental rheumatoid arthritis in mice[J]. Cytokine, 2014,69(1) :87-93.
  • 8Langhans B, Braunschweiger I, Arndt S, et al. Core-spe- cific adaptive regulatory T-cells in different outcomes of hepatitis C[J]. Clinical Science, 2010, 119( 2): 97-109.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部